News
-
-
PRESS RELEASE
Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies
Onco-Innovations announces advancement in manufacturing partner's process development for proprietary PNKP inhibitor technology. Extension of engagement with MCS for market awareness services -
-
PRESS RELEASE
Onco-Innovations Announces Successful Scale-Up of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for its PNKP Inhibitor Technology Program
Onco-Innovations successfully scales up key intermediates A83 and B4, advancing its CMC program for nanoparticle-based PNKP inhibitor drug ONC010. Collaborates with Dalton Pharma Services for process optimization and future GMP manufacturing -
-
PRESS RELEASE
Onco-Innovations Advances Polymer Testing as It Moves Its PNKP Inhibitor Technology Toward IND-Enabling Studies
Onco-Innovations Limited announces advancement in analytical method for PNKP Inhibitor Technology, strengthening formulation development and scale-up for clinical manufacturing -
-
PRESS RELEASE
Onco-Innovations Announces Completion of Analytical Method Development for Monomer Intermediate 1 Supporting ONC010 Program
Onco-Innovations successfully completes milestone with Dalton Pharma Services, developing analytical method for purity determination of Intermediate 1 supporting ONC010, enhancing drug delivery system quality control -
-
PRESS RELEASE
Onco-Innovations Strengthens Executive Leadership with Appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development
Onco-Innovations appoints Dr. Islam Mohamed as CMO and Stephen M. Novak as Chief of R&D, aiming to enhance clinical and development capabilities for advancing ONC010. Strategic leadership additions for Onco's transition to clinical-stage execution
